Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TroFuse-005
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
- NCT06132958 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Endometrial Cancer
- Interventions
- Sacituzumab tirumotecan; Doxorubicin; Paclitaxel; Nab-paclitaxel; Rescue medications
- Arms
- Sacituzumab tirumotecan · Experimental
- Chemotherapy · Active comparator
- Enrollment
- 710 (estimated)
- Primary outcomes
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
- Start
- Dec 6, 2023
- Primary completion
- Jan 10, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06132958 · updated Aug 28, 2026